About this trial
Cerebral arteriovenous malformations (CAVMs) are abnormal vessels located on the surface of the brain or within the cerebral parenchyma, causing abnormal communication between the arterial and venous networks, without the interposition of the capillary bed. The main risk associated with these malformations is rupture, which causes intracranial bleeding and can lead to serious sequelae or even death. CAVMs (except those of clearly identified genetic origin \[\< 5%\], such as mutations associated with Rendu-Osler disease) have long been considered to be of non-genetic origin.
However, somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway have recently been identified in surgical specimens of cAVMs. Furthermore, targeted inhibition of this pathway is effective in treating these malformations in animals and appears to be effective in extracranial arteriovenous malformations, particularly superficial ones.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Treated for cAVM
Indication for embolisation treatment decided upon during a multidisciplinary team meeting (MDT)
Venous embolisation, with or without arterial embolisation
Disqualifiers
Extra-cerebral arteriovenous malformations
Under legal protection measures (guardianship/curatorship, etc.)
Pregnancy
Not eligible for intravenous treatment
Trial design
Treatments tested in this trial
- Search for activating somatic genetic mutations